98 related articles for article (PubMed ID: 11943050)
1. Prescription duration after drug copay changes in older people: methodological aspects.
Schneeweiss S; Maclure M; Soumerai SB
J Am Geriatr Soc; 2002 Mar; 50(3):521-5. PubMed ID: 11943050
[TBL] [Abstract][Full Text] [Related]
2. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.
Schneeweiss S; Soumerai SB; Glynn RJ; Maclure M; Dormuth C; Walker AM
CMAJ; 2002 Mar; 166(6):737-45. PubMed ID: 11944760
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.
Schneeweiss S; Walker AM; Glynn RJ; Maclure M; Dormuth C; Soumerai SB
N Engl J Med; 2002 Mar; 346(11):822-9. PubMed ID: 11893794
[TBL] [Abstract][Full Text] [Related]
4. Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia.
Duetz MS; Schneeweiss S; Maclure M; Abel T; Glynn RJ; Soumerai SB
Clin Ther; 2003 Jan; 25(1):273-84. PubMed ID: 12637126
[TBL] [Abstract][Full Text] [Related]
5. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.
Schneeweiss S; Soumerai SB; Maclure M; Dormuth C; Walker AM; Glynn RJ
Clin Pharmacol Ther; 2003 Oct; 74(4):388-400. PubMed ID: 14534526
[TBL] [Abstract][Full Text] [Related]
6. Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents.
Schneeweiss S; Dormuth C; Grootendorst P; Soumerai SB; Maclure M
Med Care; 2004 Jul; 42(7):653-60. PubMed ID: 15213490
[TBL] [Abstract][Full Text] [Related]
7. Health services utilization with reference drug pricing of histamine(2) receptor antagonists in British Columbia elderly.
Hazlet TK; Blough DK
Med Care; 2002 Aug; 40(8):640-9. PubMed ID: 12187178
[TBL] [Abstract][Full Text] [Related]
8. Trends and determinants of prescription drug expenditures in the elderly: data from the British Columbia Pharmacare Program.
Anderson GM; Kerluke KJ; Pulcins IR; Hertzman C; Barer ML
Inquiry; 1993; 30(2):199-207. PubMed ID: 8314608
[TBL] [Abstract][Full Text] [Related]
9. A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences.
Schneeweiss S; Maclure M; Dormuth CR; Glynn RJ; Canning C; Avorn J
Clin Pharmacol Ther; 2006 Apr; 79(4):379-88. PubMed ID: 16580906
[TBL] [Abstract][Full Text] [Related]
10. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia.
Marshall JK; Grootendorst PV; O'Brien BJ; Dolovich LR; Holbrook AM; Levy AR
CMAJ; 2002 Jun; 166(13):1655-62. PubMed ID: 12126319
[TBL] [Abstract][Full Text] [Related]
11. Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly.
Liu SZ; Romeis JC
Med Care; 2003 Dec; 41(12):1331-42. PubMed ID: 14668666
[TBL] [Abstract][Full Text] [Related]
12. Prescription drugs: issues of cost, coverage, and quality.
Copeland C
EBRI Issue Brief; 1999 Apr; (208):1-21. PubMed ID: 10539445
[TBL] [Abstract][Full Text] [Related]
13. Using policy simulation to predict drug plan expenditure when planning reimbursement changes.
Dormuth CR; Burnett S; Schneeweiss S
Pharmacoeconomics; 2005; 23(10):1021-30. PubMed ID: 16235975
[TBL] [Abstract][Full Text] [Related]
14. Reference-based pricing of prescription drugs: exploring the equivalence of angiotensin-converting-enzyme inhibitors.
Bourgault C; Elstein E; Le Lorier J; Suissa S
CMAJ; 1999 Aug; 161(3):255-60. PubMed ID: 10463046
[TBL] [Abstract][Full Text] [Related]
15. Impact of a Medicaid copayment policy on prescription drug and health services utilization in a fee-for-service Medicaid population.
Hartung DM; Carlson MJ; Kraemer DF; Haxby DG; Ketchum KL; Greenlick MR
Med Care; 2008 Jun; 46(6):565-72. PubMed ID: 18520310
[TBL] [Abstract][Full Text] [Related]
16. Health care policy evaluation using longitudinal insurance claims data: an application of the panel Tobit estimator.
Grootendorst PV
Health Econ; 1997; 6(4):365-82. PubMed ID: 9285230
[TBL] [Abstract][Full Text] [Related]
17. Adverse events associated with prescription drug cost-sharing among poor and elderly persons.
Tamblyn R; Laprise R; Hanley JA; Abrahamowicz M; Scott S; Mayo N; Hurley J; Grad R; Latimer E; Perreault R; McLeod P; Huang A; Larochelle P; Mallet L
JAMA; 2001 Jan 24-31; 285(4):421-9. PubMed ID: 11242426
[TBL] [Abstract][Full Text] [Related]
18. Antidepressant medication use among First Nations peoples residing within British Columbia.
Wardman D; Khan N
Am Indian Alsk Native Ment Health Res; 2004 Nov; 11(3):43-8. PubMed ID: 15536588
[TBL] [Abstract][Full Text] [Related]
19. Prescription drug use in pregnancy: a retrospective, population-based study in British Columbia, Canada (2001-2006).
Daw JR; Mintzes B; Law MR; Hanley GE; Morgan SG
Clin Ther; 2012 Jan; 34(1):239-249.e2. PubMed ID: 22169049
[TBL] [Abstract][Full Text] [Related]
20. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment.
Schneeweiss S; Patrick AR; Maclure M; Dormuth CR; Glynn RJ
Circulation; 2007 Apr; 115(16):2128-35. PubMed ID: 17420348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
